Blockbuster sales of its flagship GLP-1 treatments have propelled Eli Lilly And Co.‘s first-quarter earnings, prompting a prominent Wall Street analyst to defend the stock’s valuation and highlight the disruptive potential of its new oral weight-loss drug. Fueling The ‘Love Affair’ Eli Lilly's revenue skyrocketed 56% year-over-year to $19.8 billion during its first-quarter 2026, driven primarily by the astronomical volume demand for its metabolic and weight-management medications. Following the earnings ...